<DOC>
	<DOCNO>NCT02369939</DOCNO>
	<brief_summary>Randomized study investigate efficacy deep regional hyperthermia patient anal carcinoma treat standard radiochemotherapy MMC 5-FU .</brief_summary>
	<brief_title>Effects Deep Regional Hyperthermia Patients With Anal Carcinoma Treated Standard Radiochemotherapy</brief_title>
	<detailed_description>Pat . anal carcinoma treat standard radiochemotherapy Mitomycin C 5-FU experimental arm receive deep regional hyperthermia ( 6x ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Histologically proven anal squamous cell carcinoma ( SCC ) ( WHO 2004 ) , include anal canal carcinoma ( UICC 2002 ) anal margin carcinoma ( UICC 2002 ) All stage except T1 N0 M0 local excision ( UICC 2002 ) Age ≥ 18 year ECOG Status 01 Patients understand protocol sign informed consent form Sufficient bone marrow function : WBC ≥ 3,0 x 10^9/l , Platelets ≥ 100 x 10^9/l , Hemoglobin ≥ 10 g/dl Sufficient liver function : Bilirubin &lt; 1,5 mg/dl , SGOT , SGPT , alkaline phosphatase , gGT le 3 time upper limit normal Stage T1 N0 M0 local excision ( UICC 2002 ) Uncontrolled , severe cardiac dysfunction ( NYHA III/IV ) Preexisting uncontrolled cardiac disease , sign cardiac failure , rhythm disturbance require therapy Myocardial infarction within past 12 month Congestive heart failure Complete bundle branch block New York Heart Association ( NYHA ) class III IV heart disease Chronic inflammatory disease intestine Active intractable uncontrolled infection Chronic diarrhea ( &gt; NCI CTCGrad 1 ) Acute thrombosis Collagen vascular disease Cardiac pacemaker HIVinfection ; Patients hepatitis A B virus infection , HPV infection Patients receive immune suppressive treatment include Devices preclude deep regional hyperthermia ( Endoprosthesis , stent vascular system , acute thrombosis ) Any metal implant ( exception nonclustered marker clip ) Conditions preclude application fractionate pelvic radiotherapy Conditions preclude regular followup Pregnant breast feed woman Prior pelvic radiotherapy Prior chemotherapy Drug addiction Ontreatment participation trial Prior concurrent malignancy leucemia ( ≤ 5 year prior enrolment study ) except anal cancer nonmelanoma skin cancer cervical carcinoma FIGO stage 01 patient continuously diseasefree The presence increase radiation sensitivity , example ataxia teleangiectatica , similar Psychological , familial , sociological , geographical condition would preclude study compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>anal carcinoma</keyword>
	<keyword>hyperthermia</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>radiochemotherapy</keyword>
</DOC>